{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/53541"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/53541","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Transcatheter aoritc valve implantation as a first-line strategy in low-risk young adults with aortic stenosis","abstract":"Aortic stenosis is the most common valvular heart disease requiring intervention in the developed world, and once severe and symptomatic, replacement of the valve is the only intervention that can treat it. For decades this meant surgical aortic valve replacement, but the development of transcatheter aortic valve implantation and its progressive extension down the surgical risk strata, from inoperable to high, intermediate, and finally low surgical risk, has reshaped clinical practice and the major guidelines. The furthest extension of this evidence has raised the question of whether transcatheter aortic valve implantation is appropriate as a first-line strategy in the young, low-risk patient. This thesis argues that the young low-risk patient constitutes a clinically distinct problem that cannot be resolved by extrapolation from the elderly cohorts in whom the therapy was tested. The young patient differs from the typical trial participant in the predominance of bicuspid aortic valve anatomy, which was systematically excluded from the pivotal randomized trials and which complicates transcatheter deployment. As well as this, the young patient has a remaining life expectancy of three or four decades rather than one. It is this durability-to-life-expectancy ratio that transforms the treatment decision from a comparison of short-term outcomes into a problem of lifetime management, since a young recipient is expected to outlive any currently available bioprosthetic valve and to require one or more reinterventions across the ensuing decades. The pivotal low-risk trials, PARTNER 3 and Evolut Low Risk, demonstrated an early advantage for the transcatheter approach in bleeding, atrial fibrillation, recovery, hospital stay, and health-related quality of life, and this early benefit constitutes the strongest part of the case for extending the therapy to younger patients. Yet this advantage diminishes as follow-up lengthens, with longer-term data showing a convergence of outcomes with surgery. The case against first-line transcatheter aortic valve implantation in the young depends on the long-term durability of the transcatheter valve, the feasibility of a lifetime reintervention strategy contingent upon coronary access and the anatomical capacity to accommodate a second transcatheter valve, and the burden of complications such as permanent pacemaker implantation and paravalvular leak whose consequences compound across a longer life. Finally, the conventional framing of transcatheter against conventional surgical replacement is argued to be too narrow for the young patient, in whom alternative strategies, most notably the Ross procedure, may represent a more lifetime-relevant comparator that has not been tested against transcatheter aortic valve implantation directly. The conclusion of this thesis is that the present evidence neither condemns nor endorses the transcatheter approach in the young low-risk patient as a first-line strategy, because the outcomes that matter most to this group, durability beyond ten years, bicuspid performance, and reintervention feasibility, remain inadequately measured. Future work should include randomized trials enrolling genuinely younger patients with follow-up of sufficient duration, and direct comparison of transcatheter aortic valve implantation against the Ross procedure.","abstract_html":"Aortic stenosis is the most common valvular heart disease requiring intervention in the developed world, and once severe and symptomatic, replacement of the valve is the only intervention that can treat it. For decades this meant surgical aortic valve replacement, but the development of transcatheter aortic valve implantation and its progressive extension down the surgical risk strata, from inoperable to high, intermediate, and finally low surgical risk, has reshaped clinical practice and the major guidelines. The furthest extension of this evidence has raised the question of whether transcatheter aortic valve implantation is appropriate as a first-line strategy in the young, low-risk patient. This thesis argues that the young low-risk patient constitutes a clinically distinct problem that cannot be resolved by extrapolation from the elderly cohorts in whom the therapy was tested. The young patient differs from the typical trial participant in the predominance of bicuspid aortic valve anatomy, which was systematically excluded from the pivotal randomized trials and which complicates transcatheter deployment. As well as this, the young patient has a remaining life expectancy of three or four decades rather than one. It is this durability-to-life-expectancy ratio that transforms the treatment decision from a comparison of short-term outcomes into a problem of lifetime management, since a young recipient is expected to outlive any currently available bioprosthetic valve and to require one or more reinterventions across the ensuing decades. The pivotal low-risk trials, PARTNER 3 and Evolut Low Risk, demonstrated an early advantage for the transcatheter approach in bleeding, atrial fibrillation, recovery, hospital stay, and health-related quality of life, and this early benefit constitutes the strongest part of the case for extending the therapy to younger patients. Yet this advantage diminishes as follow-up lengthens, with longer-term data showing a convergence of outcomes with surgery. The case against first-line transcatheter aortic valve implantation in the young depends on the long-term durability of the transcatheter valve, the feasibility of a lifetime reintervention strategy contingent upon coronary access and the anatomical capacity to accommodate a second transcatheter valve, and the burden of complications such as permanent pacemaker implantation and paravalvular leak whose consequences compound across a longer life. Finally, the conventional framing of transcatheter against conventional surgical replacement is argued to be too narrow for the young patient, in whom alternative strategies, most notably the Ross procedure, may represent a more lifetime-relevant comparator that has not been tested against transcatheter aortic valve implantation directly. The conclusion of this thesis is that the present evidence neither condemns nor endorses the transcatheter approach in the young low-risk patient as a first-line strategy, because the outcomes that matter most to this group, durability beyond ten years, bicuspid performance, and reintervention feasibility, remain inadequately measured. Future work should include randomized trials enrolling genuinely younger patients with follow-up of sufficient duration, and direct comparison of transcatheter aortic valve implantation against the Ross procedure.","abstract_has_math":false,"creators":["Abdelwahab, Mohamed"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Van Houten, Trudy M."],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T20:06:00Z","subjects":["Medicine","Ross procedure","SAVR","Surgical aortic valve replacement","TAVI","Transcatheter aortic valve implantation","Transcatheter aortic valve replacement"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/53541","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/53541","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F53541","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Van Houten, Trudy M."]},{"key":"dc:creator","label":"Author","values":["Abdelwahab, Mohamed"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-09-24T18:48:47Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2026-09-24T18:48:47Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-09-15T16:15:38Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicine","Ross procedure","SAVR","Surgical aortic valve replacement","TAVI","Transcatheter aortic valve implantation","Transcatheter aortic valve replacement"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/53541"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2026"]},{"key":"dc:description.abstract","label":"Abstract","values":["Aortic stenosis is the most common valvular heart disease requiring intervention in the developed world, and once severe and symptomatic, replacement of the valve is the only intervention that can treat it. For decades this meant surgical aortic valve replacement, but the development of transcatheter aortic valve implantation and its progressive extension down the surgical risk strata, from inoperable to high, intermediate, and finally low surgical risk, has reshaped clinical practice and the major guidelines. The furthest extension of this evidence has raised the question of whether transcatheter aortic valve implantation is appropriate as a first-line strategy in the young, low-risk patient. This thesis argues that the young low-risk patient constitutes a clinically distinct problem that cannot be resolved by extrapolation from the elderly cohorts in whom the therapy was tested. The young patient differs from the typical trial participant in the predominance of bicuspid aortic valve anatomy, which was systematically excluded from the pivotal randomized trials and which complicates transcatheter deployment. As well as this, the young patient has a remaining life expectancy of three or four decades rather than one. It is this durability-to-life-expectancy ratio that transforms the treatment decision from a comparison of short-term outcomes into a problem of lifetime management, since a young recipient is expected to outlive any currently available bioprosthetic valve and to require one or more reinterventions across the ensuing decades. The pivotal low-risk trials, PARTNER 3 and Evolut Low Risk, demonstrated an early advantage for the transcatheter approach in bleeding, atrial fibrillation, recovery, hospital stay, and health-related quality of life, and this early benefit constitutes the strongest part of the case for extending the therapy to younger patients. Yet this advantage diminishes as follow-up lengthens, with longer-term data showing a convergence of outcomes with surgery. The case against first-line transcatheter aortic valve implantation in the young depends on the long-term durability of the transcatheter valve, the feasibility of a lifetime reintervention strategy contingent upon coronary access and the anatomical capacity to accommodate a second transcatheter valve, and the burden of complications such as permanent pacemaker implantation and paravalvular leak whose consequences compound across a longer life. Finally, the conventional framing of transcatheter against conventional surgical replacement is argued to be too narrow for the young patient, in whom alternative strategies, most notably the Ross procedure, may represent a more lifetime-relevant comparator that has not been tested against transcatheter aortic valve implantation directly. The conclusion of this thesis is that the present evidence neither condemns nor endorses the transcatheter approach in the young low-risk patient as a first-line strategy, because the outcomes that matter most to this group, durability beyond ten years, bicuspid performance, and reintervention feasibility, remain inadequately measured. Future work should include randomized trials enrolling genuinely younger patients with follow-up of sufficient duration, and direct comparison of transcatheter aortic valve implantation against the Ross procedure."]},{"key":"dc:title","label":"Title","values":["Transcatheter aoritc valve implantation as a first-line strategy in low-risk young adults with aortic stenosis"]}]}],"canonical_facts":{"dc:contributor.advisor":["Van Houten, Trudy M."],"dc:creator":["Abdelwahab, Mohamed"],"dc:date.accessioned":["2026-09-24T18:48:47Z"],"dc:date.available":["2026-09-24T18:48:47Z"],"dc:date.issued":["2026"],"dc:date.updated":["2026-09-15T16:15:38Z"],"dc:description":["2026"],"dc:description.abstract":["Aortic stenosis is the most common valvular heart disease requiring intervention in the developed world, and once severe and symptomatic, replacement of the valve is the only intervention that can treat it. For decades this meant surgical aortic valve replacement, but the development of transcatheter aortic valve implantation and its progressive extension down the surgical risk strata, from inoperable to high, intermediate, and finally low surgical risk, has reshaped clinical practice and the major guidelines. The furthest extension of this evidence has raised the question of whether transcatheter aortic valve implantation is appropriate as a first-line strategy in the young, low-risk patient. This thesis argues that the young low-risk patient constitutes a clinically distinct problem that cannot be resolved by extrapolation from the elderly cohorts in whom the therapy was tested. The young patient differs from the typical trial participant in the predominance of bicuspid aortic valve anatomy, which was systematically excluded from the pivotal randomized trials and which complicates transcatheter deployment. As well as this, the young patient has a remaining life expectancy of three or four decades rather than one. It is this durability-to-life-expectancy ratio that transforms the treatment decision from a comparison of short-term outcomes into a problem of lifetime management, since a young recipient is expected to outlive any currently available bioprosthetic valve and to require one or more reinterventions across the ensuing decades. The pivotal low-risk trials, PARTNER 3 and Evolut Low Risk, demonstrated an early advantage for the transcatheter approach in bleeding, atrial fibrillation, recovery, hospital stay, and health-related quality of life, and this early benefit constitutes the strongest part of the case for extending the therapy to younger patients. Yet this advantage diminishes as follow-up lengthens, with longer-term data showing a convergence of outcomes with surgery. The case against first-line transcatheter aortic valve implantation in the young depends on the long-term durability of the transcatheter valve, the feasibility of a lifetime reintervention strategy contingent upon coronary access and the anatomical capacity to accommodate a second transcatheter valve, and the burden of complications such as permanent pacemaker implantation and paravalvular leak whose consequences compound across a longer life. Finally, the conventional framing of transcatheter against conventional surgical replacement is argued to be too narrow for the young patient, in whom alternative strategies, most notably the Ross procedure, may represent a more lifetime-relevant comparator that has not been tested against transcatheter aortic valve implantation directly. The conclusion of this thesis is that the present evidence neither condemns nor endorses the transcatheter approach in the young low-risk patient as a first-line strategy, because the outcomes that matter most to this group, durability beyond ten years, bicuspid performance, and reintervention feasibility, remain inadequately measured. Future work should include randomized trials enrolling genuinely younger patients with follow-up of sufficient duration, and direct comparison of transcatheter aortic valve implantation against the Ross procedure."],"dc:identifier.uri":["https://hdl.handle.net/2144/53541"],"dc:language.iso":["en_US"],"dc:subject":["Medicine","Ross procedure","SAVR","Surgical aortic valve replacement","TAVI","Transcatheter aortic valve implantation","Transcatheter aortic valve replacement"],"dc:title":["Transcatheter aoritc valve implantation as a first-line strategy in low-risk young adults with aortic stenosis"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T20:06:00Z"}